Emerging Roles of Endocannabinoids as Key Lipid Mediators for a Successful Pregnancy DOI Open Access
Alessandro Rava, Viviana Trezza

International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(6), P. 5220 - 5220

Published: March 9, 2023

In recent years, Cannabis use/misuse for treating pregnancy-related symptoms and other chronic conditions has increased among pregnant women, favored by decriminalization and/or legalization of its recreational uses in addition to easy accessibility. However, there is evidence that prenatal exposure might have adverse consequences on pregnancy progression a deleterious impact proper neurodevelopmental trajectories the offspring. Maternal use could interfere with complex finely controlled role performed endocannabinoid system reproductive physiology, impairing multiple gestational processes from blastocyst implantation parturition, long-lasting intergenerational effects. this review, we discuss current clinical preclinical regarding endocannabinoids development, function, immunity maternal–fetal interface, focusing constituents each these processes. We also intrinsic limitations available studies future perspectives challenging research field.

Language: Английский

Assessment of Medical Cannabis and Health-Related Quality of Life DOI Creative Commons
Thomas R. Arkell, Luke A. Downey, Amie C. Hayley

et al.

JAMA Network Open, Journal Year: 2023, Volume and Issue: 6(5), P. e2312522 - e2312522

Published: May 9, 2023

Importance The use of cannabis as a medicine is becoming increasingly prevalent. Given the diverse range conditions being treated with medical cannabis, well vast array products and dose forms available, clinical evidence incorporating patient-reported outcomes may help determine safety efficacy. Objective To assess whether patients using report improvements in health-related quality life over time. Design, Setting, Participants This retrospective case series study was conducted at network specialist clinics (Emerald Clinics) located across Australia. were who received treatment for any indication point between December 2018 May 2022. Patients followed up every mean (SD) 44.6 (30.1) days. Data to 15 follow-ups reported. Statistical analysis from August September Exposure Medical cannabis. Product types cannabinoid content varied time accordance treating physician’s judgement. Main Outcomes Measures main outcome measure assessed 36-Item Short Form Health Survey (SF-36) questionnaire. Results In this 3148 patients, 1688 (53.6%) female; 820 (30.2%) employed; age 55.9 (18.7) years baseline before treatment. Chronic noncancer pain most common (68.6% [2160 3148]), by cancer (6.0% [190 insomnia (4.8% [152 anxiety (4.2% [132 3148]). After commencing reported significant relative on all 8 domains SF-36, these mostly sustained controlling potential confounders regression model, associated an improvement 6.60 (95% CI, 4.57-8.63) points 18.31 15.86-20.77) SF-36 scores, depending domain (all P < .001). Effect sizes (Cohen d ) ranged 0.21 0.72. A total 2919 adverse events reported, including 2 that considered serious. Conclusions Relevance study, life, which Adverse rarely serious but common, highlighting need caution prescribing

Language: Английский

Citations

38
The prevalence of cannabis use disorders in people who use medicinal cannabis: A systematic review and meta-analysis DOI Creative Commons
Danielle Dawson, Daniel Stjepanović, Valentina Lorenzetti

et al.

Drug and Alcohol Dependence, Journal Year: 2024, Volume and Issue: 257, P. 111263 - 111263

Published: March 8, 2024

The prevalence of cannabis use disorders (CUDs) in people who recreationally has been estimated at 22%, yet there is a dearth literature exploring CUDs among medicinal cannabis. We aimed to systematically review the In our systematic and meta-analysis, we followed PRISMA guidelines searched three databases (PsychInfo, Embase PubMed) identify studies examining Metaanalyses were calculated on CUDs. Prevalence estimates pooled across different periods (recent 6-12 months) using DSM-IV DSM-5. conducted 14 eligible publications, assessing with diagnostic criteria, providing data for 3681 participants from five countries. demonstrated that demographic factors, mental health problems management chronic pain associated an elevated risk A meta-analyses was For individuals past months, 29% (95% CI: 21-38%) as per DSM-5 criteria. Similar observed (24%, 14-38%) same period. substantial comparable recreational reasons, emphasizing need ongoing research monitor

Language: Английский

Citations

15
Cumulative Social Disadvantage and Medicinal Cannabis Use Among Younger Adults in Rural Communities: A Mixed Methods Approach DOI

Sharon Lipperman-Kreda,

Emile Sanders,

Julie Peach

et al.

Journal of Psychoactive Drugs, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 10

Published: Jan. 7, 2025

This mixed-methods study investigated the role of medicinal cannabis use among younger adults who live in rural communities and experience high levels cumulative social disadvantage (CSD). Results are based on cross-sectional surveys online interviews with 153 (18-35-years old) California. We assessed participants' CSD (high, medium, low) examined associations perceived general physical mental health (MUC). Qualitative analyses were then conducted to better understand roles lives participants versus low CSD. High was associated poorer MUC, but not past month use. findings emphasized significant MUC for young people reduce stress manage health. Findings suggest need address inequities communities, such as increasing access care, reliance managing

Language: Английский

Citations

1
Cannabis Dependence Among Georgian Small-Scale Cannabis Growers: Results of a Cross-Sectional Online Survey DOI
Tamar Mgebrishvili, Irma Kirtadze, Ali Mirzazadeh

et al.

Journal of Psychoactive Drugs, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 10

Published: Feb. 7, 2025

The study aims to assess cannabis dependency among individuals who cultivate for medical and/or recreational purposes. Participants included growers cultivated personal use, social supply, caregiving activities, or illegal sales. Between December 2020 and August 2021, we conducted an online cross-sectional survey Georgian growers. We used the International Cannabis Cultivation Questionnaire measure purpose of growing Severity Dependence Scale (SDS). Logistic regression analysis was factors associated with dependency. Out 218 growers, 193 (88.5%) grew their use. Among participants, 132 (68%) 61 (32%) it overall prevalence use 37.7%. In multiple logistic analysis, users (AOR 0.39, P-value < .05) had lower odds developing compared users. Growers purposes were more likely consume on a daily almost basis. majority (illegal) products consumption, mostly This group higher odd those

Language: Английский

Citations

1
Cannabis use prevalence, patterns, and reasons for use among patients with cancer and survivors in a state without legal cannabis access DOI
Erin A. McClure, Kyle J. Walters, Rachel L. Tomko

et al.

Supportive Care in Cancer, Journal Year: 2023, Volume and Issue: 31(7)

Published: June 29, 2023

Language: Английский

Citations

22
An Overview of the Potential for Pharmacokinetic Interactions Between Drugs and Cannabis Products in Humans DOI Creative Commons
Dolly Andrea Caicedo, Clara Pérez‐Mañá, Magı́ Farré

et al.

Pharmaceutics, Journal Year: 2025, Volume and Issue: 17(3), P. 319 - 319

Published: March 1, 2025

Cannabis is the most commonly used illicit substance worldwide. Recent years have seen an increase in cannabis consumption, and with new approvals therapeutic indications, there are challenges minimizing risks interactions between cannabis-based products, prescription drugs, other approved substances of abuse. Thus, identifying enzymes metabolizing cannabinoid drugs their relationship crucial for understanding potential effects simultaneous use. This article offers a comprehensive review pharmacokinetic as well It also compiles existing evidence these describes clinical outcomes associated inhibition or induction various enzymes.

Language: Английский

Citations

1
Medical Cannabis for the Treatment of Migraine in Adults: A Review of the Evidence DOI Creative Commons
Babasola O. Okusanya, Breanne E. Lott,

John Ehiri

et al.

Frontiers in Neurology, Journal Year: 2022, Volume and Issue: 13

Published: May 30, 2022

Background Medical cannabis (MC) has been hypothesized as an alternative therapy for migraines, given the undesirable side effects of current migraine medications. The objective this review was to assess effectiveness and safety MC in treatment adults. Methods We searched PubMed, EMBASE, PsycINFO, CINAHL, Web Science eligible studies adults aged 18 years older. Two reviewers independently screened eligibility. A narrative synthesis included conducted. Results total 12 publications involving 1,980 participants Italy United States America were included. significantly reduced nausea vomiting associated with attacks after 6 months use. Also, number days 30 days, frequency headaches per month. 51% more effective reducing migraines than non-cannabis products. Compared amitriptyline, aborted some (11.6%) users frequency. While use occurrence medication overuse (MOH), adverse events mostly mild occurred 43.75% patients who used oral cannabinoid preparations. Conclusions There is promising evidence that may have a beneficial effect on onset duration However, well-designed experimental MC's treating are needed support hypothesis.

Language: Английский

Citations

26
Nutrition, endocannabinoids, and the use of cannabis: An overview for the nutrition clinician DOI Creative Commons
Lindsey Russell,

Kayla Condo,

Tiffany DeFlorville

et al.

Nutrition in Clinical Practice, Journal Year: 2024, Volume and Issue: 39(4), P. 815 - 823

Published: March 30, 2024

The endocannabinoid system (ECs) is composed of multiple signaling compounds and receptors within the central peripheral nervous along with various organs, including gut, liver, skeletal muscle. ECs has been implicated in metabolism, gut motility, eating behaviors. altered disease states such as obesity. Recent studies have clarified role microbiome nutrition on ECs. Exogenous cannabinoid (CB) use, either organic or synthetic, stimulates through CB1 CB2 receptors. However, CBs unclear regard to optimization treat states. This review briefly summarizes effect exogenous metabolism nutrition. With increased legalization cannabis, there a corresponding use United States. Therefore, clinicians need be aware both benefits harm cannabis overall status, well gaps knowledge for future research guideline development.

Language: Английский

Citations

6
Perceptions, Experiences, and Patterns of Cannabis Use in Individuals with Mood and Anxiety Disorders in the Context of Cannabis Legalization and Medical Cannabis Program in Canada – A Qualitative Study DOI
Ankita Das, Christian S. Hendershot, M. Ishrat Husain

et al.

Pharmacopsychiatry, Journal Year: 2024, Volume and Issue: 57(03), P. 141 - 151

Published: March 11, 2024

Abstract Introduction Perceptions of cannabis as a potential medical treatment for mood and anxiety disorders have been increasing in the context legalizations, availability, programs, though current evidence predominately indicates risks negative effects use (CU) on mental health outcomes. This study aims to understand motivations, perceptions, effects, patterns CU individuals with disorders. Methods Thirty-six adult patients diagnosed or disorders, obsessive-compulsive disorder, posttraumatic stress disorder who were currently using completed an in-depth qualitative interview individual experiences, their CU. The thematic analysis focused phases sources products information. Results Reported motivations initiation included curiosity, peer pressure, dissatisfaction conventional treatments. Factors such psychotropic coping symptoms insomnia contributed continuation More including cognitive dysfunction, worsening mood, symptoms, acknowledged ongoing Concerning findings common before age 18, combined recreational CU, rare consultation professionals harms. Discussion Findings indicate complexity population. reported beneficial specific should be further investigated. emphasize patient-provider dialogue both Information from this can contribute inform development education, prevention, intervention strategies.

Language: Английский

Citations

4
Bidirectional relationships between pain and patterns of cannabis and tobacco use in a US nationally representative sample DOI
Dana Rubenstein, Michael J. Green, Maggie M. Sweitzer

et al.

Pain, Journal Year: 2024, Volume and Issue: unknown

Published: Aug. 21, 2024

Abstract One-fifth of US adults experience chronic pain, which is associated with increased tobacco and cannabis use. Although bidirectional relationships between pain have been demonstrated, pathways use, co-use are understudied. We aimed to estimate the effects (1) substance use (exclusive tobacco) on later intensity, (2) intensity Data were from 31,983 in biennial surveys (2015-2021) nationally representative longitudinal Population Assessment Tobacco Health Study (n = 71,055 pairs consecutive surveys; T1 T2). Past-week was dichotomized (≤4/10 no/low pain; >4/10 moderate/severe pain). Mutually exclusive categories (past 30 days) no cannabis/tobacco use; co-use. Logistic regression assessed whether affected at T2. Multinomial models status Compared T1, (OR: 2.29 [95% CI: 2.09-2.51]), (2.00 [1.86-2.14]), (1.35 [1.13-1.61]) all Moderate/severe odds (2.43 [2.22-2.66]), (2.12 [1.98-2.28]), (1.46 [1.29-1.65]) compared T2, T2 Findings demonstrated indicate potential synergy respect pain.

Language: Английский

Citations

4